Literature DB >> 24770611

Addressing statin adverse effects in the clinic: the 5 Ms.

Daniel H Katz1, Sunny S Intwala1, Neil J Stone2.   

Abstract

With the release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, emphasis has been placed on using evidence-based intensity of therapy to reduce atherosclerotic cardiovascular disease (ASCVD) risk, rather than focusing on goal cholesterol levels. Before initiating therapy, however, it is critical that physicians and patients discuss 4 key topics: (1) the benefit of ASCVD risk reduction, (2) medication adverse effects, (3) drug-drug interactions, and (4) patient preferences. To facilitate discussion of statin adverse effects, we present here an evidence-based review of the 5 Ms of statin adverse effects: metabolism, muscle, medication interactions, major organ effects, and memory. "Metabolism" represents the small risk of new-onset diabetes that comes with statins, which is highest in those with diabetes risk factors. "Muscle" requires discussion of the wide range of muscle symptoms that occur with statins but emphasizes that these have been no more prevalent than those experienced with placebo in randomized controlled trials (RCTs). "Medication interactions" emphasize that statins interact with numerous medications. Interaction profiles vary widely between statins, and patients should be made aware of the most common interactions with their prescription. "Major organ effects" prompt the physician to review the possibility of a transient transaminitis as well as the recent observation of rare acute kidney injury with statin use. Both are rare and do not require routine monitoring. Finally, "memory" references the recent observational data suggesting statins may contribute to memory loss and confusion, both of which have not been observed in RCTs and resolve with drug cessation. Reviewing these common effects has the possibility to strengthen the doctor-patient relationship and boost both medication adherence and patient satisfaction.
© The Author(s) 2014.

Entities:  

Keywords:  hypercholesterolemia; lipids; statin

Mesh:

Substances:

Year:  2014        PMID: 24770611     DOI: 10.1177/1074248414529622

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  8 in total

Review 1.  Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines.

Authors:  Seth S Martin; Laurence S Sperling; Michael J Blaha; Peter W F Wilson; Ty J Gluckman; Roger S Blumenthal; Neil J Stone
Journal:  J Am Coll Cardiol       Date:  2015-04-07       Impact factor: 24.094

2.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

3.  Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models.

Authors:  Yusuke Kobayashi; Hiroyasu Kashima; Ren-Chin Wu; Jin-Gyoung Jung; Jen-Chun Kuan; Jinghua Gu; Jianhua Xuan; Lori Sokoll; Kala Visvanathan; Ie-Ming Shih; Tian-Li Wang
Journal:  Clin Cancer Res       Date:  2015-06-24       Impact factor: 12.531

Review 4.  Shared Decision-Making and Patient Empowerment in Preventive Cardiology.

Authors:  Swetha Kambhampati; Tamara Ashvetiya; Neil J Stone; Roger S Blumenthal; Seth S Martin
Journal:  Curr Cardiol Rep       Date:  2016-05       Impact factor: 2.931

Review 5.  Statin Prescribing in the Elderly: Special Considerations.

Authors:  M Leya; N J Stone
Journal:  Curr Atheroscler Rep       Date:  2017-10-11       Impact factor: 5.113

Review 6.  Improving medication adherence in hypercholesterolemia: challenges and solutions.

Authors:  Justin Gatwood; James E Bailey
Journal:  Vasc Health Risk Manag       Date:  2014-11-06

Review 7.  Statins, Muscle Disease and Mitochondria.

Authors:  Radha Ramachandran; Anthony S Wierzbicki
Journal:  J Clin Med       Date:  2017-07-25       Impact factor: 4.241

8.  Statins interfere with the attachment of S. cerevisiae mtDNA to the inner mitochondrial membrane.

Authors:  Angela Cirigliano; Antonia Amelina; Beatrice Biferali; Alberto Macone; Chiara Mozzetta; Michele Maria Bianchi; Mattia Mori; Bruno Botta; Elah Pick; Rodolfo Negri; Teresa Rinaldi
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.